復星醫藥(02196.HK):“18復藥01”將於8月14日本息兑付及摘牌
格隆匯8月3日丨復星醫藥(02196.HK)發佈公吿,上海復星醫藥(集團)股份有限公司2018年公開發行公司債券(第一期)(簡稱:18復藥01、代碼:143422)將於2023年8月14日支付自2022年8月13日至2023年8月12日期間(即最後一個年度)利息和本期債券本金。本期債券本年度票面利率(計息年利率)為3.50%,每手本期債券面值為人民幣1,000.00元,派發利息為人民幣35.00元(税前)。債權登記日為2023年8月11日。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.